137 related articles for article (PubMed ID: 20454514)
1. Loss of transforming growth factor-beta signaling in mammary fibroblasts enhances CCL2 secretion to promote mammary tumor progression through macrophage-dependent and -independent mechanisms.
Hembruff SL; Jokar I; Yang L; Cheng N
Neoplasia; 2010 May; 12(5):425-33. PubMed ID: 20454514
[TBL] [Abstract][Full Text] [Related]
2. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks.
Cheng N; Bhowmick NA; Chytil A; Gorksa AE; Brown KA; Muraoka R; Arteaga CL; Neilson EG; Hayward SW; Moses HL
Oncogene; 2005 Jul; 24(32):5053-68. PubMed ID: 15856015
[TBL] [Abstract][Full Text] [Related]
3. Noncanonical TGF-β signaling during mammary tumorigenesis.
Parvani JG; Taylor MA; Schiemann WP
J Mammary Gland Biol Neoplasia; 2011 Jun; 16(2):127-46. PubMed ID: 21448580
[TBL] [Abstract][Full Text] [Related]
4. Targeted gene silencing of CCL2 inhibits triple negative breast cancer progression by blocking cancer stem cell renewal and M2 macrophage recruitment.
Fang WB; Yao M; Brummer G; Acevedo D; Alhakamy N; Berkland C; Cheng N
Oncotarget; 2016 Aug; 7(31):49349-49367. PubMed ID: 27283985
[TBL] [Abstract][Full Text] [Related]
5. Attenuated TGFB signalling in macrophages decreases susceptibility to DMBA-induced mammary cancer in mice.
Sun X; Bernhardt SM; Glynn DJ; Hodson LJ; Woolford L; Evdokiou A; Yan C; Du H; Robertson SA; Ingman WV
Breast Cancer Res; 2021 Mar; 23(1):39. PubMed ID: 33761981
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer-associated macrophages promote tumorigenesis by suppressing succinate dehydrogenase in tumor cells.
Gómez V; Eykyn TR; Mustapha R; Flores-Borja F; Male V; Barber PR; Patsialou A; Green R; Panagaki F; Li CW; Fruhwirth GO; Ros S; Brindle KM; Ng T
Sci Signal; 2020 Oct; 13(652):. PubMed ID: 33023985
[TBL] [Abstract][Full Text] [Related]
7. Obesity promotes breast cancer by CCL2-mediated macrophage recruitment and angiogenesis.
Arendt LM; McCready J; Keller PJ; Baker DD; Naber SP; Seewaldt V; Kuperwasser C
Cancer Res; 2013 Oct; 73(19):6080-93. PubMed ID: 23959857
[TBL] [Abstract][Full Text] [Related]
8. LYVE-1-expressing Macrophages Modulate the Hyaluronan-containing Extracellular Matrix in the Mammary Stroma and Contribute to Mammary Tumor Growth.
Elfstrum AK; Rumahorbo AH; Reese LE; Nelson EV; McCluskey BM; Schwertfeger KL
Cancer Res Commun; 2024 May; 4(5):1380-1397. PubMed ID: 38717149
[TBL] [Abstract][Full Text] [Related]
9. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis.
Bonapace L; Coissieux MM; Wyckoff J; Mertz KD; Varga Z; Junt T; Bentires-Alj M
Nature; 2014 Nov; 515(7525):130-3. PubMed ID: 25337873
[TBL] [Abstract][Full Text] [Related]
10. Biomaterial Scaffolds as Pre-metastatic Niche Mimics Systemically Alter the Primary Tumor and Tumor Microenvironment.
Aguado BA; Hartfield RM; Bushnell GG; Decker JT; Azarin SM; Nanavati D; Schipma MJ; Rao SS; Oakes RS; Zhang Y; Jeruss JS; Shea LD
Adv Healthc Mater; 2018 May; 7(10):e1700903. PubMed ID: 29521008
[TBL] [Abstract][Full Text] [Related]
11. Tumor microenvironment profoundly modifies functional status of macrophages: peritoneal and tumor-associated macrophages are two very different subpopulations.
Rodríguez D; Silvera R; Carrio R; Nadji M; Caso R; Rodríguez G; Iragavarapu-Charyulu V; Torroella-Kouri M
Cell Immunol; 2013; 283(1-2):51-60. PubMed ID: 23850963
[TBL] [Abstract][Full Text] [Related]
12. FAM171B stabilizes vimentin and enhances CCL2-mediated TAM infiltration to promote bladder cancer progression.
Hu WM; Li M; Ning JZ; Tang YQ; Song TB; Li LZ; Zou F; Cheng F; Yu WM
J Exp Clin Cancer Res; 2023 Nov; 42(1):290. PubMed ID: 37915048
[TBL] [Abstract][Full Text] [Related]
13. A C-terminal fragment of adhesion protein fibulin-7 inhibits growth of murine breast tumor by regulating macrophage reprogramming.
Chakraborty P; Dash SP; Dalpati N; Kumar P; Jain D; Sarangi PP
FEBS J; 2021 Feb; 288(3):803-817. PubMed ID: 32297473
[TBL] [Abstract][Full Text] [Related]
14. CCL2 chemokine inhibition primes the tumor vasculature for improved nanomedicine delivery and efficacy.
Möckel D; Bartneck M; Niemietz P; Wagner M; Ehling J; Rama E; Weiler M; Gremse F; Eulberg D; Pola R; Pechar M; Etrych T; Storm G; Kiessling F; Tacke F; Lammers T
J Control Release; 2024 Jan; 365():358-368. PubMed ID: 38016488
[TBL] [Abstract][Full Text] [Related]
15. Thrombospondin-4 mediates hyperglycemia- and TGF-beta-induced inflammation in breast cancer.
Muppala S; Xiao R; Gajeton J; Krukovets I; Verbovetskiy D; Stenina-Adognravi O
Int J Cancer; 2021 Apr; 148(8):2010-2022. PubMed ID: 33320955
[TBL] [Abstract][Full Text] [Related]
16. Interleukin 4 Controls the Pro-Tumoral Role of Macrophages in Mammary Cancer Pulmonary Metastasis in Mice.
Rodriguez-Tirado C; Entenberg D; Li J; Qian BZ; Condeelis JS; Pollard JW
Cancers (Basel); 2022 Sep; 14(17):. PubMed ID: 36077870
[TBL] [Abstract][Full Text] [Related]
17. Investigating Chemokine-Matrix Networks in Breast Cancer: Tenascin-C Sets the Tone for CCL2.
Gschwandtner M; Gammage AN; Deligne C; Mies LFM; Domaingo A; Murdamoothoo D; Loustau T; Schwenzer A; Derler R; Carapito R; Koch M; Mörgelin M; Orend G; Kungl AJ; Midwood KS
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176074
[TBL] [Abstract][Full Text] [Related]
18. Deciphering Stromal Changes between Metastatic and Non-metastatic Canine Mammary Carcinomas.
Ettlin J; Bauer A; Opitz L; Malbon A; Markkanen E
J Mammary Gland Biol Neoplasia; 2023 Jul; 28(1):14. PubMed ID: 37391533
[TBL] [Abstract][Full Text] [Related]
19. Reticular Fibroblasts Expressing the Transcription Factor WT1 Define a Stromal Niche that Maintains and Replenishes Splenic Red Pulp Macrophages.
Bellomo A; Mondor I; Spinelli L; Lagueyrie M; Stewart BJ; Brouilly N; Malissen B; Clatworthy MR; Bajénoff M
Immunity; 2020 Jul; 53(1):127-142.e7. PubMed ID: 32562599
[TBL] [Abstract][Full Text] [Related]
20. Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors.
Kwan A; Winder N; Atkinson E; Al-Janabi H; Allen RJ; Hughes R; Moamin M; Louie R; Evans D; Hutchinson M; Capper D; Cox K; Handley J; Wilshaw A; Kim T; Tazzyman SJ; Srivastava S; Ottewell P; Vadakekolathu J; Pockley G; Lewis CE; Brown JE; Danson SJ; Conner J; Muthana M
Mol Cancer Ther; 2021 Mar; 20(3):589-601. PubMed ID: 33298589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
